Navigation Links
Driver of anthrax toxicity could lead to late-stage therapy

nd the "protective antigen carrier" of anthrax toxin, allowing its delivery into cells.

The new findings "reveal a previously unsuspected biological role" for LRP6, a gene earlier found to play important roles in pathways underlying early development and cell proliferation, the researchers said. The discovery also suggests potential new avenues for treating late-stage anthrax disease, they added.

While antibiotics, such as Cipro, can fight the anthrax bacteria when the disease is caught early, such drugs do nothing to dispel the accumulated toxin, the researchers explained. In contrast, drugs that target the host protein LRP6, or other components of the host machinery integral to the toxin's internalization, might offer a novel method to prevent the toxin from infiltrating and killing cells.

"Our discovery of the role of LRP6 in anthrax toxicity and the demonstration that antibodies directed against the extracellular domain of LRP6 can protect cells grown in culture against killing by anthrax toxin suggest that the immunological targeting of LRP6 may prove useful in protecting against the effects of accumulated toxin during the late stages of anthrax disease when antibacterial methods normally are no longer of therapeutic value," the researchers wrote.


'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Scientists seek answers on what activates deadly anthrax spores
2. Antibodies from plants protect against anthrax
3. Defensins neutralize anthrax toxin
4. Critical step traced in anthrax infection
5. US Army plans to bulk-buy anthrax
6. New antibody shows promise as cure for anthrax
7. Effective, safe anthrax vaccine can be grown in tobacco plants
8. UCSD study finds anthrax toxins also harmful to fruit flies
9. Scientists design potent anthrax toxin inhibitor
10. Newly discovered protein kills anthrax bacteria by exploding their cell walls
11. Combating anthrax: Results of study published this month as researchers look for a better vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Driver anthrax toxicity could lead late stage therapy

(Date:9/29/2014)... order to support the world,s needs to make ... more, new and more efficient catalytic materials and ... including several from Wayne State University, is tackling ... grant from the National Science Foundation. , The ... Multicomponent Materials for Electrocatalytic Cascade Reactions," was to ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... review article published online in Behavioral Brain Research ... the brain as a result of chronic alcohol exposure ... , Clinical assessments and research indicate that individuals ... sleep. This can occur when people are actively drinking, ... are abstaining. , "Sleep-wake disturbances can last for ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... 14, 2012 The latest episode in the American ... podcast series describes the development of a new test ... Amid concerns about the threat of terrorist attacks, ... and other nations. One such team has developed a ...
... Irvine researchers have discovered how Salmonella , a bacterium ... in humans, thrives in the digestive tract despite the immune ... explain why Salmonella is difficult to eradicate and ... with Salmonella suffer from diarrhea, fever and abdominal ...
... A parking lot at the edge of the University ... emerging concern for the environment and human health. ... journal Environmental Science & Technology , has found that ... lots throughout the nation, has significant health and ecosystem implications. ...
Cached Biology News:New test could help track down and prosecute terrorists 2UCI-led study uncovers how Salmonella avoids the body's immune response 2UNH research adds to mounting evidence against popular pavement sealcoat 2
(Date:9/29/2014)... , September 29, 2014 Atox ... severe infections, today announced that the Biomedical Advanced Research ... Bio with a contract valued up to $24 million ... treat Necrotizing Soft Tissue Infections (NSTI) and potentially infections ... in sepsis. BARDA awarded the contract to ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/28/2014)... Modality Solutions, a company ... highly regulated industries, is pleased to announce Consulting ... Transport Simulation Laboratoryâ„¢ software at the 12th Annual ... Forum in Boston, September 29 through October 3. ... software on October 2, day two of the ...
(Date:9/27/2014)... available in German . ... only used for precisely surveying the surface topology of ... is done by exciting the atoms to fluoresce under ... This secondary emission provides information about the location and ... precise. However, the lighter elements of the periodic table ...
Breaking Biology Technology:Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3'Multi-spectra glasses' for scanning electron microscopy 2
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by Amgen Inc. in,connection ... 90mg., Barr,s Abbreviated New Drug Application (ANDA) ... product was received as acceptable,for filing by the ...
... are to be used in clinical trials ... on a path to finally cure diabetes, ... recently declared its commitment to support Spring Point,Project, a Minnesota non-profit ... of islet tissue for,diabetes care., (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), ...
... as an Antipsychotic Agent with Less Potential for ... Weight Gain and Metabolic Risks, SAN DIEGO, July ... announced that the United States Patent and,Trademark Office (USPTO) ... would provide broad coverage for a pharmaceutical,composition of zonisamide ...
Cached Biology Technology:Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 2Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 3Spring Point Project Gains Support of Lions Clubs 2Spring Point Project Gains Support of Lions Clubs 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4